Alamar Biosciences' NULISA Platform Dominates AAIC 2026 with 140+ Presentations
Event summary
- Alamar Biosciences' NULISA platform featured in over 140 scientific presentations at AAIC 2026, a fourfold increase from the previous conference.
- Company to host workshop showcasing eMTBR-Tau and BD-pTau217 assays, measuring these alongside 220+ proteins on a single NULISAseq panel.
- Data suggests combined amyloid and tau biomarkers enable earlier Alzheimer’s detection and more precise disease staging.
- Thomas K. Karikari of University of Pittsburgh highlights multiplex data as key to advancing beyond pTau-217 as the default readout.
The big picture
Alamar Biosciences' dominance at AAIC 2026 underscores the growing industry shift toward multiplex biomarker profiling in Alzheimer’s research. The ability to measure tau pathology, neuroinflammation, and neurodegeneration markers simultaneously positions NULISA as a potential standard for early disease detection. This strategic advantage could accelerate adoption among researchers reliant on government funding, though competition remains intense in the proteomics market.
What we're watching
- Adoption Pace
- How quickly NULISA's multiplex protein profiling will replace single-marker pTau-217 assays in clinical research.
- Regulatory Pathway
- Whether Alamar can secure marketing authorizations for future clinical or diagnostic products.
- Competitive Positioning
- The pace at which competitors develop comparable multiplex proteomics platforms for Alzheimer’s research.
Related topics